As a healthcare professional, you want the best for your patients. However, tackling tinnitus requires specialized expertise. Partner with the world's leading tinnitus specialists. We collaborate with your practice to provide patients with clinically proven, long-term relief through specialized neurological desensitization.
Your Tinnitus Patients Finally Have Somewhere to Go
If you treat patients with tinnitus — whether you are an ENT specialist, a GP, a neurologist, or a psychiatrist — you already know the problem. Tinnitus is one of the most common conditions you encounter, and one of the least satisfying to treat. The standard options are limited: tell patients to learn to live with it, refer to an audiologist who may or may not have tinnitus expertise, or prescribe medication that addresses the anxiety but not the underlying neurological mechanism. Neuromonics changes that equation. For the first time, you have a clinically-validated, evidence-backed treatment you can confidently recommend — one that addresses the actual neurological mechanism of tinnitus, not just its symptoms.
How Tinnitus Works — and Why Most Treatments Fall Short
Tinnitus is not an ear condition. It is a brain condition that begins in the ear. When cochlear hair cells are damaged by noise, aging, or ototoxic medications, the auditory cortex compensates by amplifying its own neural activity — generating the phantom sound your patient hears. But the distress comes from two additional neurological processes: attentional filters that label the tinnitus signal as important and keep it in conscious awareness, and the limbic system's emotional response that triggers anxiety and fight-or-flight activation every time the tinnitus is noticed. Treatments that address only the ear — masking devices, white noise, earwax removal — provide temporary relief but do not change the brain's underlying response. Effective tinnitus treatment must target all three neurological processes simultaneously.
The clinical implication
This is why Neuromonics produces lasting results where other approaches fail. The personalized acoustic stimulation reduces auditory cortex hyperactivity. The music-based delivery retrains the attentional filter system. And the carefully engineered program promotes desensitization of the limbic emotional response. All three processes addressed simultaneously — which is what 20 years of clinical evidence supports.
Clinical Evidence: 83% Success Rate Across 10 Independent Studies
Neuromonics has the most extensive clinical evidence base of any tinnitus treatment currently available. Ten peer-reviewed studies across US and Australian medical centers — seven of them conducted by independent researchers — consistently demonstrate clinically significant reduction in tinnitus disturbance in 83% of patients. Success is defined as a 40% or greater reduction in Tinnitus Reaction Questionnaire (TRQ) score — the gold standard validated clinical outcome measure for tinnitus research. The Veterans Affairs Hollywood study achieved 96% success. The largest real-world study, involving 470 patients in private practice, achieved 92% success.
83%
Average success rate
Across 10 clinical studies
1,033+
Patients studied
US & Australian medical centers
96%
Highest single-study result
Hollywood VA (Veterans Affairs)
Study
Subjects
Location
Type
Success*
Hollywood VA
35
Veterans Affairs US
Independent
96%
Private Practice
470
Australia
Neuromonics
92%
T2 – NTT vs SOC
50
Australia
Neuromonics
90%
Tavori TRI
25
Australia
Independent
90%
T3 – Phase 1 vs 2
35
Australia
Neuromonics
86%
CALM Study
51
United States
Independent
81%
Lions Ear Institute
29
Australia
Independent
75%
Tavora AAA
70
US / Australia
Independent
75%
Australian Veterans
50
Veterans Affairs AU
Independent
74%
Oregon Tinnitus
24
United States
Independent
72%
Total / Average
1,033
83%
*Success = clinically significant reduction in tinnitus disturbance. 10 studies across US & Australian medical centers, 2007–2010.
🏥
Independent verification
7 of 10 studies conducted by independent researchers — not Neuromonics
👨⚕️
Veterans Affairs validated
96% success at Hollywood VA — among the most rigorous real-world settings
📊
Largest real-world study
470-patient private practice study — 92% success rate
How to Refer a Patient to Neuromonics
1
Identify the candidate
Neuromonics is appropriate for patients with subjective tinnitus causing moderate to severe distress — affecting sleep, concentration, emotional wellbeing, or quality of life. There are no contraindications for the acoustic therapy itself. Patients with pulsatile tinnitus should have vascular causes ruled out before referral.
2
Direct them to the app
The patient downloads the Neuromonics app (iOS) and completes an audiogram-based onboarding process. The app personalizes the acoustic stimulation to their specific hearing profile — no clinic visit required for the initial treatment phase.
3
Set expectations
Initial improvement is typically noticed within 2-4 weeks. Significant measurable improvement occurs at 3-6 months of daily use. The patient uses the app for 2-3 hours daily during the active treatment phase, reducing to maintenance use as neurological desensitization consolidates.
4
Monitor and support
You can track patient progress through the Neuromonics provider portal. Patients who combine Neuromonics with CBT for tinnitus distress show the strongest outcomes. For patients with co-occurring hearing loss, hearing aids should be prescribed concurrently.
Patients with subjective tinnitus causing moderate to severe distress — affecting sleep, concentration, emotional wellbeing, or daily functioning. Patients with pulsatile tinnitus should have vascular causes ruled out before referral.
Neuromonics matches your patient with a certified, trained audiologist in our network. The audiologist conducts a virtual assessment, fits the patient with their personalized acoustic program, and guides them through the two-stage treatment protocol entirely online.
We recommend patients first see their own physician or audiologist for an initial assessment and audiogram. After that, the entire Neuromonics protocol is administered virtually — all appointments, counseling, and treatment adjustments are conducted online. No required in-person visits with Neuromonics.
TRT relies on broadband noise and natural habituation over 12–24 months with extensive clinic time. Neuromonics achieves the same success rate in approximately a third of the therapy time, using personalized music-based acoustic stimulation that targets all three neurological processes simultaneously.
83% of patients achieve a clinically significant 40% or greater reduction in Tinnitus Reaction Questionnaire score. The biggest gains occur in the first two months, with continued improvement thereafter. Active treatment runs 6–8 months followed by a maintenance phase.
There are no known contraindications to the acoustic therapy for subjective tinnitus. The treatment is non-invasive and non-pharmaceutical. Patients with pulsatile tinnitus should have vascular causes excluded first. Patients with significant anxiety or depression may benefit from concurrent psychological support.
Elevated anxiety can reduce treatment efficacy if not addressed. For patients with significant psychological comorbidities, concurrent referral to a psychologist or CBT specialist is strongly recommended alongside the Neuromonics protocol.
Yes. Ten peer-reviewed studies across US and Australian medical centers involving 1,033+ patients demonstrate 83% average success rate — defined as a 40% or greater reduction in TRQ score. Seven of the ten studies were conducted by independent researchers. The Hollywood VA study achieved 96% success.
Give your tinnitus patients an answer
Neuromonics is the only clinically-validated neurological desensitization program available as a consumer app. 83% of patients achieve a 40%+ reduction in TRQ score. 20 years of evidence. Free for your patients to try.
For patients whose primary goal is achieving long-term, lasting relief from tinnitus disturbance, Neuromonics should be considered a first-line treatment.
91% of patients
achieve significant reduction in tinnitus disturbance (Davis, Paki & Hanley, Ear and Hearing 2007)
97% would recommend
would recommend Neuromonics to others — the strongest patient satisfaction measure in tinnitus treatment research
Half the clinic time of TRT
required compared to TRT, with the same success rate achieved in a third of the therapy time
Our proprietary algorithms modify music to account for individual hearing profiles, providing targeted stimulation to the auditory system that promotes neurological desensitization to tinnitus.
Our proprietary algorithms modify music to account for individual hearing profiles, providing targeted stimulation to the auditory system that promotes neurological desensitization to tinnitus.
Our proprietary algorithms modify music to account for individual hearing profiles, providing targeted stimulation to the auditory system that promotes neurological desensitization to tinnitus.
